National Health Research Institutes

Taigen Biotechnology Company, Ltd.

Taigen Biotechnology

Chu-Chung Lin

Der-Ren Hwang

Chiung-Tong Chen

Ming-Chu Hsu

Wen-Tai Li

Shu-Jen Chen

Pei-Chin Cheng

Yibin Xiang

Chi-Feng Yen

Chi-Hsin Richard King

Chih-Wei Chang

Jiing-Jyh Jan

Jen-Fuh Liu

Wen-Chang Chen

Shan-Yen Chou

Han-Pei Hsu

Hung-Chuan Chen

Chen-Fu Liu

Chih-Ming Chen

Kuo-Feng Tseng

Pin Lo

Yo-Chin Liu

Kuang-Yuan Lee

Chiayn Chiang

Rong-Jiunn Chen

Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: Ais CRor N; Ais CRRor NR; Ais CR'R&#x2032; or NR&#x2032;; each of R, R, R&#x2032;, R, R&#x2032;, R, R, R&#x2032;, R, R&#x2032;, R, and R&#x2032;, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, Calkyl, Calkenyl, Calkynyl, Calkoxy, Calkenyloxy, Calkylcarbonyl, Calkyloxycarbonyl, Calkylamine, Ccarbocyclyl, or Cheterocyclyl; or Rand R, R&#x2032; and R&#x2032;, or Rand R&#x2032;, together with the adjacent atom to which they are each attached, form Ccarbocyclyl or Cheterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.

Cap-dependent endonuclease inhibitors

A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which Ris C-Calkyl or C-Ccycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.

Trans-isomeric heterocyclic compounds and preparation thereof

A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, 

Solid dispersion formulation

This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.

HCV protease inhibitors

This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R, R, R, R, and n are defined herein.

Methods of 1H-indol-3-yl-2-oxoacetamide compounds

The invention relates to novel imidazolamino compounds. Also disclosed are methods of treating cancer by using one of these compounds and pharmaceutical compositions containing one of these compounds.

Imidazolamino compounds

A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R, R, R, R, and n are as defined herein.

Use of 1H-indol-3-yl-2-oxoacetamide compounds

This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in the specification. 

Aminoquinoline compounds

The invention is based on the discovery that certain 3-oxoacetamideindolyl compounds have potent anticancer and anti-angiogenic activity. The 3-oxoacetamideindolyl compounds are of the following formula.In this formula, each Ris independently isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently C3-C10 cycloalkyl, C4-C10 cycloalkenyl, isoxazolyl, furanyl, thiophenyl, thiazolyl, imidazolyl, pyridyl, or heterocyclyl, each being optionally substituted with 1-4 independent R. Each Ris independently H, NO, halo, CN, R, OR, COR, SR, NRR, C(O)R, C(O)NRR, OC(O)R, S(O)R, S(O)NRR, NRC(O)NRR, NRC(O)R, NR(COOR), NRS(O)NRR, NRS(O)R, or S(O)OR.

Indol-3-YL-2-oxoacetamide compounds and methods of use thereof

Growing community of inventors

Taipei, Taiwan

Chu-Chung Lin